ReviewWorld journal of urology2020
Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.
Review in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis.Frontiers in medicine · 2021Pooled it
- Integrated Single-Cell and Bulk RNA Sequencing Reveals Inflammatory Microenvironment and Glycolysis-Driven Epithelial Proliferation in Benign Prostatic Hyperplasia.Journal of inflammation research · 2026Article
- Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles.Toxicology reports · 2025Article
- Gland- and cell-level heterogeneity in the prostate: A narrative review of related diseases.Current urology · 2025Article
- Network pharmacology and animal experiments revealed the protective effects of Guilong prescription on chronic prostatitis and its possible mechanisms.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Medical Advancements in Benign Prostatic Hyperplasia Treatments.Current urology reports · 2024Review
- QSAR, molecular docking, MD simulations, and ADMET screening identify potentialIn silico pharmacology · 2024Article
- Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia.BMC complementary medicine and therapies · 2023Article
- Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia and associated LUTS.Continence (Amsterdam, Netherlands) · 2023Article
- Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia.BMC urology · 2022Article
- Triple-disease etiology is common for LUTS in octogenarians: a neuro-urological approach.International urology and nephrology · 2021Article
- Unmet Medical Needs of Patients with Benign Prostate Enlargement.Journal of clinical medicine · 2020Article
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.Frontiers in pharmacology · 2020Review
- Mitigating Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Ameliorating Sexual Function and Psychological Well-Being in Older Men.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe benign prostatic syndrome, comprising lower urinary tract symptomatology secondary to benign prostatic hyperplasia/enlargement, represents a major health care issue in westernized countries. The pharmacological management involves alpha-adrenoceptor antagonists, intervention into the hormonal control of prostate growth using inhibitors of the enzyme 5-alpha-reductase, and stimulation of the nitric oxide/cyclic GMP pathway by tadalafil, an inhibitor of the phosphodiesterase type 5.
methodsThis review summarizes the achievements which have been made in the development of drug candidates assumed to offer opportunities as beneficial treatment options in the management of the benign prostatic syndrome.
resultsA review of the literature has revealed that the line of development is focusing on drugs interfering with peripheral neuromuscular/neuronal mechanisms (nitric oxide donor drugs, agonists/antagonists of endogenous peptides, botulinum toxin, NX-1207), the steroidal axis (cetrorelix) or the metabolic turn-over (lonidamine), as well as the combination of drugs already established in the treatment of lower urinary tract symptomatology/benign prostatic hyperplasia (phosphodiesterase 5 inhibitor plus alpha-adrenoceptor antagonist).
conclusionMany research efforts have provided the basis for the development of new therapeutic modalities for the management of lower urinary tract dysfunctions, some of which might be offered to the patients in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.